CN103298928B - 用于激活辅助性t细胞的方法 - Google Patents

用于激活辅助性t细胞的方法 Download PDF

Info

Publication number
CN103298928B
CN103298928B CN201180058552.2A CN201180058552A CN103298928B CN 103298928 B CN103298928 B CN 103298928B CN 201180058552 A CN201180058552 A CN 201180058552A CN 103298928 B CN103298928 B CN 103298928B
Authority
CN
China
Prior art keywords
hla
molecule
drb1
peptide
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180058552.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103298928A (zh
Inventor
杉山治夫
十河真司
佐藤政芳
北本龙生
后藤义博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
Otsuka Pharmaceutical Co Ltd
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, International Institute of Cancer Immunology Inc filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN103298928A publication Critical patent/CN103298928A/zh
Application granted granted Critical
Publication of CN103298928B publication Critical patent/CN103298928B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180058552.2A 2010-10-05 2011-10-04 用于激活辅助性t细胞的方法 Active CN103298928B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-225806 2010-10-05
JP2010225806 2010-10-05
PCT/JP2011/072874 WO2012046730A1 (ja) 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610191489.4A Division CN105802910A (zh) 2010-10-05 2011-10-04 用于激活辅助性t细胞的方法

Publications (2)

Publication Number Publication Date
CN103298928A CN103298928A (zh) 2013-09-11
CN103298928B true CN103298928B (zh) 2016-04-20

Family

ID=45927725

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610191489.4A Pending CN105802910A (zh) 2010-10-05 2011-10-04 用于激活辅助性t细胞的方法
CN201180058552.2A Active CN103298928B (zh) 2010-10-05 2011-10-04 用于激活辅助性t细胞的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610191489.4A Pending CN105802910A (zh) 2010-10-05 2011-10-04 用于激活辅助性t细胞的方法

Country Status (21)

Country Link
US (2) US10654892B2 (OSRAM)
EP (1) EP2626418B8 (OSRAM)
JP (3) JP6134139B2 (OSRAM)
KR (3) KR20140009168A (OSRAM)
CN (2) CN105802910A (OSRAM)
AR (1) AR083295A1 (OSRAM)
AU (1) AU2011313327B2 (OSRAM)
BR (1) BR112013008230A2 (OSRAM)
CA (1) CA2813557C (OSRAM)
CO (1) CO6710946A2 (OSRAM)
EA (1) EA037547B1 (OSRAM)
ES (1) ES2849187T3 (OSRAM)
IL (2) IL225536B (OSRAM)
MX (2) MX361299B (OSRAM)
MY (1) MY170306A (OSRAM)
NZ (2) NZ609460A (OSRAM)
PH (1) PH12013500654A1 (OSRAM)
SG (3) SG189287A1 (OSRAM)
TW (2) TWI608099B (OSRAM)
WO (1) WO2012046730A1 (OSRAM)
ZA (1) ZA201303056B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
EP2119778B1 (en) 2007-02-27 2015-11-04 International Institute of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2626418B8 (en) * 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CA2884366A1 (en) * 2012-09-12 2014-03-20 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
ES2805337T3 (es) * 2012-12-17 2021-02-11 Otsuka Pharma Co Ltd Método para activar células T auxiliares
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
SI2945647T1 (sl) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni peptidi WT-1 in postopki za uporabo le-teh
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
WO2015129790A1 (ja) * 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
CA2974066C (en) 2014-12-25 2025-05-06 International Institute Of Cancer Immunology, Inc. METHOD FOR MODIFYING A T LYMPHOCYTE POPULATION
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
WO2018088439A1 (ja) 2016-11-09 2018-05-17 国立大学法人大阪大学 Ｔ細胞集団の改変方法
WO2018101309A1 (ja) * 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
CN111741972A (zh) * 2017-12-27 2020-10-02 大日本住友制药株式会社 Wt1衍生肽的缀合物和包含其的组合物
WO2019160099A1 (ja) * 2018-02-15 2019-08-22 大塚製薬株式会社 がん抗原ペプチド
BR112021003031A8 (pt) * 2018-08-22 2023-05-02 Hutchinson Fred Cancer Res Imunoterapia direcionada a antígenos kras ou her2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1696027A (zh) * 2004-05-12 2005-11-16 领先技术公司 封装套鼓

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
HK1039782B (en) 1998-09-30 2008-11-14 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
NZ521430A (en) 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
JP3728439B2 (ja) 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
JP4229832B2 (ja) 2001-06-29 2009-02-25 忠範 真弓 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
JP4480580B2 (ja) 2002-09-20 2010-06-16 株式会社癌免疫研究所 Ｗｔ１置換型ペプチド
KR20120054644A (ko) 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
ATE538809T1 (de) 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
JP4886507B2 (ja) 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CN105315347A (zh) 2005-11-30 2016-02-10 株式会社癌免疫研究所 新型肽化合物
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
EP2385117B1 (en) 2006-02-22 2016-07-27 International Institute of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
EP2980219B1 (en) 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
EP2119778B1 (en) 2007-02-27 2015-11-04 International Institute of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2626418B8 (en) * 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
ES2805337T3 (es) 2012-12-17 2021-02-11 Otsuka Pharma Co Ltd Método para activar células T auxiliares

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1696027A (zh) * 2004-05-12 2005-11-16 领先技术公司 封装套鼓

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Peptide Epitopes from the Wilms Tumor 1 Oncoprotein Stimulate CD4 + and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells";Rena J. May 等;《Clinical Cancer Research》;20070801;第13卷(第15期);摘要，表1，第4548页右栏最后一段-4549页左栏第一段 *
"The Wilms Tumor Antigen Is a Novel Target for Human CD4+ Regulatory T Cells: Implications for Immunotherapy";Cynthia Lehe 等;《Cancer Research》;20080801;第68卷(第15期);第6350-6359页 *

Also Published As

Publication number Publication date
EP2626418A1 (en) 2013-08-14
TWI608099B (zh) 2017-12-11
US20130266958A1 (en) 2013-10-10
JP2018093870A (ja) 2018-06-21
IL225536B (en) 2019-03-31
ES2849187T3 (es) 2021-08-16
SG10201508252PA (en) 2015-11-27
US10654892B2 (en) 2020-05-19
WO2012046730A1 (ja) 2012-04-12
NZ609460A (en) 2015-07-31
CN103298928A (zh) 2013-09-11
TW201623616A (zh) 2016-07-01
NZ703560A (en) 2016-11-25
KR20200018738A (ko) 2020-02-19
KR20190034359A (ko) 2019-04-01
KR102079480B1 (ko) 2020-02-19
JP6134139B2 (ja) 2017-05-24
AU2011313327B2 (en) 2015-10-22
SG189287A1 (en) 2013-05-31
IL225536A0 (en) 2013-06-27
CA2813557C (en) 2021-05-04
TW201217525A (en) 2012-05-01
JPWO2012046730A1 (ja) 2014-02-24
EP2626418B1 (en) 2020-12-09
EP2626418A4 (en) 2014-02-19
PH12013500654A1 (en) 2013-05-06
IL245440A0 (en) 2016-06-30
MX2013003884A (es) 2013-07-05
US20200354405A1 (en) 2020-11-12
CN105802910A (zh) 2016-07-27
BR112013008230A2 (pt) 2016-06-14
US12415833B2 (en) 2025-09-16
JP6298101B2 (ja) 2018-03-20
CA2813557A1 (en) 2012-04-12
KR102171794B1 (ko) 2020-10-29
SG10202108581TA (en) 2021-09-29
KR20140009168A (ko) 2014-01-22
EP2626418B8 (en) 2021-03-24
EA201390509A1 (ru) 2013-08-30
AU2011313327A1 (en) 2013-05-02
JP2017006120A (ja) 2017-01-12
AR083295A1 (es) 2013-02-13
MY170306A (en) 2019-07-17
CO6710946A2 (es) 2013-07-15
EA037547B1 (ru) 2021-04-12
MX361299B (es) 2018-11-30
ZA201303056B (en) 2013-12-23
MX2018008436A (es) 2021-12-08

Similar Documents

Publication Publication Date Title
CN103298928B (zh) 用于激活辅助性t细胞的方法
CN101384716B (zh) Hla-a*3303限制性wt1肽和包含此肽的药物组合物
CN104995203B (zh) 辅助性t细胞的活化方法
HK1188465A (en) Method for activating helper t cell
HK1188465B (en) Method for activating helper t cell

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210303

Address after: Japan Osaka suita

Patentee after: International Institute of Cancer Immunology, Inc.

Address before: Osaka Japan

Patentee before: International Institute of Cancer Immunology, Inc.

Patentee before: OTSUKA PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right